Kailera Therapeutics (NASDAQ:KLRA) Stock Jumps 7.1% - Here's What Happened

Key Points

• Kailera Therapeutics shares rose 7.1% to $14.67, up from a prior close of $13.70; trading volume was about 23% below its average.
• Canaccord Genuity initiated coverage with a Buy rating and a $44 price target. Analysts’ consensus is “Moderate Buy,” with an average target of $43.
• The clinical-stage biotech reported a quarterly loss of $0.74 per share, beating analysts’ expected loss of $1.55 per share by $0.81.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) traded up 7.1% during trading on Tuesday. The stock traded as high as $14.89 and last traded at $14.67. Approximately 680,169 shares were traded during trading, a decline of 23% from the average session volume of 884,994 shares. The stock had previously closed at $13.70.

Wall Street Analysts Forecast Growth

KLRA has been the subject of a number of analyst reports. Canaccord Genuity Group assumed coverage on Kailera Therapeutics in a report on Monday. They issued a "buy" rating and a $44.00 price target for the company. Weiss Ratings upgraded Kailera Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $43.00.

Kailera Therapeutics Price Performance

The business's 50 day moving average price is $12.73 and its 200 day moving average price is $17.65. The firm has a market cap of $1.88 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($1.55) by $0.81. As a group, analysts predict that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Hedge Funds Weigh In On Kailera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cibc World Market Inc. raised its stake in Kailera Therapeutics by 4.8% in the 3rd quarter. Cibc World Market Inc. now owns 37,181 shares of the company's stock valued at $425,000 after purchasing an additional 1,705 shares during the last quarter. Commonwealth Equity Services LLC purchased a new position in Kailera Therapeutics in the 3rd quarter valued at $134,000. Tidal Investments LLC acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $309,000. Profund Advisors LLC acquired a new stake in Kailera Therapeutics during the 3rd quarter worth $216,000. Finally, Alps Advisors Inc. grew its holdings in shares of Kailera Therapeutics by 31.1% during the third quarter. Alps Advisors Inc. now owns 171,739 shares of the company's stock worth $1,961,000 after buying an additional 40,739 shares in the last quarter.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company's pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.